Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections
File(s)RSV_Adult_Biomarkers_Wiseman.doc (128 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
BACKGROUND: . Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in young infants. However, it is also a significant pathogen in older adults. Validated biomarkers of RSV disease severity would benefit diagnostics, treatment decisions, and prophylactic interventions. This review summarizes knowledge of biomarkers for RSV disease in adults. METHODS: A literature review was performed using Ovid Medline, Embase, Global health, Scopus, and Web of Science for articles published 1946-October 2016. Nine articles were identified plus 9 from other sources. RESULTS: From observational studies of natural infection and challenge studies in volunteers, biomarkers of RSV susceptibility or disease severity in adults were: (1) lower anti-RSV neutralizing antibodies, where neutralizing antibody (and local IgA) may be a correlate of susceptibility/severity; (2) RSV-specific CD8+ T cells in bronchoalveolar lavage fluid preinfection (subjects with higher levels had less severe illness); and (3) elevated interleukin-6 (IL-6), IL-8, and myeloperoxidase levels in the airway are indicative of severe infection. CONCLUSIONS: Factors determining susceptibility to and severity of RSV disease in adults have not been well defined. Respiratory mucosal antibodies and CD8+ T cells appear to contribute to preventing infection and modulation of disease severity. Studies of RSV pathogenesis in at-risk populations are needed.
Date Issued
2020-11-01
Date Acceptance
2020-03-01
Citation
Journal of Infectious Diseases, 2020, 222 (Suppl. 7), pp.S584-S591
ISSN
0022-1899
Publisher
Oxford University Press (OUP)
Start Page
S584
End Page
S591
Journal / Book Title
Journal of Infectious Diseases
Volume
222
Issue
Suppl. 7
Copyright Statement
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model). This is a pre-copy-editing, author-produced version of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version Dexter J Wiseman, Ryan S Thwaites, Simon B Drysdale, Sophie Janet, Gavin C Donaldson, Jadwiga A Wedzicha, Peter J Openshaw, the RESCEU Investigators, Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections, The Journal of Infectious Diseases, , jiaa063 is available online at: https://doi.org/10.1093/infdis/jiaa063
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model). This is a pre-copy-editing, author-produced version of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version Dexter J Wiseman, Ryan S Thwaites, Simon B Drysdale, Sophie Janet, Gavin C Donaldson, Jadwiga A Wedzicha, Peter J Openshaw, the RESCEU Investigators, Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections, The Journal of Infectious Diseases, , jiaa063 is available online at: https://doi.org/10.1093/infdis/jiaa063
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
National Institute for Health Research
Medical Research Council (MRC)
Medical Research Council (MRC)
Medical Research Council (MRC)
Imperial College Healthcare NHS Trust- BRC Funding
Commission of the European Communities
Wellcome Trust
Medical Research Council (MRC)
GlaxoSmithKline Biologicals
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/32227102
PII: 5813536
Grant Number
RDC04
NF-SI-0513-10150
HPRU-2012-10064
MR/R502121/1
MR/R005982/1
MR/R005982/1
RDA02
806776
214407/Z/18/Z
MR/T50256X/1
PO 3001965656
Subjects
COPD
IL-6
MPO
RESCEU
RSV
adult
biomarker
neutralizing antibody
respiratory syncytial virus
severity
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2020-03-30